Email Alert RSS
Volume 13 Issue 2
Mar.  2022
Turn off MathJax
Article Contents
Abstract
References
LI Xin, LIU Lu, LIU Zhihong, ZHAO Zhihui, LUO Qin, ZHAO Qing. Progress in the Application of Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation and Chronic Renal Insufficiency[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 302-307. DOI: 10.12290/xhyxzz.2021-0256
Citation: LI Xin, LIU Lu, LIU Zhihong, ZHAO Zhihui, LUO Qin, ZHAO Qing. Progress in the Application of Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation and Chronic Renal Insufficiency[J]. Medical Journal of Peking Union Medical College Hospital, 2022, 13(2): 302-307. DOI: 10.12290/xhyxzz.2021-0256
shu

Progress in the Application of Oral Anticoagulants in Patients with Non-valvular Atrial Fibrillation and Chronic Renal Insufficiency

  • 1.

    Center for Respiratory and Pulmonary Vascular Disease, Fuwai Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, National Center for Cardiovascular Diseases, Beijing 100037, China

  • 2.

    School of Public Health, Capital Medical University, Beijing 100069, China

Funds: 

Beijing Municipal Natural Science Foundation 7202168

CAMS Innovation Fund for Medical Sciences 2020-I2M-C&T-B-055

More Information
  • Corresponding author:

    LIU Zhihong, E-mail: zhihongliufuwai@163.com

  • Received Date: March 07, 2021
  • Accepted Date: June 15, 2021
  • Available Online: December 27, 2021
  • Issue Publish Date: March 29, 2022
    Graphical Abstract
    • Abstract
  • Oral anticoagulants can effectively reduce the risk of stroke in patients with atrial fibrillation. However, patients with atrial fibrillation and chronic renal insufficiency have an increased risk in both stroke and bleeding, making anticoagulant therapy challenging. Compared with traditional anticoagulant warfarin, non-vitamin K antagonist oral anticoagulants are non-inferior to warfarin in efficacy and safety. They don't require routine monitoring of the international normalized ratio and have better patient compliance. However, all the non-vitamin K antagonist oral anticoagulants are partially metabolized through kidneys to a varying degree, and thus their administration in patients with atrial fibrillation and chronic renal insufficiency is controversial. This review summarizes the administration of oral anticoagulants in these patients to guide clinical practice.
    • FullText(HTML)
    • References (34)
  • [1]
    Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)[J]. Eur Heart J, 2021, 42: 373-498.
    [2]
    Staerk L, Wang B, Preis SR, et al. Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study[J]. BMJ, 2018, 361: k1453.
    [3]
    Hart RG, Eikelboom JW, Brimble KS, et al. Stroke Prevention in Atrial Fibrillation Patients With Chronic Kidney Disease[J]. Can J Cardiol, 2013, 29: S71-S78. DOI: 10.1016/j.cjca.2013.04.005
    [4]
    Banerjee A, Fauchier L, Vourc'h P, et al. A Prospective Study of Estimated Glomerular Filtration Rate and Outcomes in Patients With Atrial Fibrillation: The Loire Valley Atrial Fibrillation Project[J]. Chest, 2014, 145: 1370-1382. DOI: 10.1378/chest.13-2103
    [5]
    Chan KE, Giugliano RP, Patel MR, et al. Nonvitamin K Anticoagulant Agents in Patients With Advanced Chronic Kidney Disease or on Dialysis With AF[J]. J Am Coll Cardiol, 2016, 67: 2888-2899. DOI: 10.1016/j.jacc.2016.02.082
    [6]
    Writing Group Members, January CT, Wann LS, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Heart Rhythm, 2019, 16: e66-e93. DOI: 10.1016/j.hrthm.2019.01.024
    [7]
    Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2011, 365: 981-992. DOI: 10.1056/NEJMoa1107039
    [8]
    Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation[J]. N Engl J Med, 2011, 365: 883-891. DOI: 10.1056/NEJMoa1009638
    [9]
    Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2009, 361: 1139-1151. DOI: 10.1056/NEJMoa0905561
    [10]
    Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation[J]. N Engl J Med, 2013, 369: 2093-2104. DOI: 10.1056/NEJMoa1310907
    [11]
    Toyoda K, Ninomiya T. Stroke and cerebrovascular diseases in patients with chronic kidney disease[J]. Lancet Neurol, 2014, 13: 823-833. DOI: 10.1016/S1474-4422(14)70026-2
    [12]
    Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies[J]. J Am Soc Nephrol, 2004, 15: 1307-1315. DOI: 10.1097/01.ASN.0000123691.46138.E2
    [13]
    Lee M, Saver JL, Chang KH, et al. Low glomerular filtration rate and risk of stroke: meta-analysis[J]. BMJ, 2010, 341: c4249. DOI: 10.1136/bmj.c4249
    [14]
    Elkin PL, Mullin S, Mardekian J, et al. Using Artificial Intelligence With Natural Language Processing to Combine Electronic Health Record's Structured and Free Text Data to Identify Nonvalvular Atrial Fibrillation to Decrease Strokes and Death: Evaluation and Case-Control Study[J]. J Med Internet Res, 2021, 23: e28946. DOI: 10.2196/28946
    [15]
    Wattanaruengchai P, Nathisuwan S, Karaketklang K, et al. Comparison of the HAS-BLED versus ORBIT Scores in Predicting Major Bleeding Among Asians Receiving the Direct-Acting Oral Anticoagulants[J]. Br J Clin Pharmacol, 2021. doi: 10.1111/bcp.15145.[Epub ahead of print].
    [16]
    Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation[J]. Europace, 2021, 23: 1612-1676.
    [17]
    Dahal K, Kunwar S, Rijal J, et al. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies[J]. Chest, 2016, 149: 951-959. DOI: 10.1378/chest.15-1719
    [18]
    Hart RG, Pearce LA, Asinger RW, et al. Warfarin in atrial fibrillation patients with moderate chronic kidney disease[J]. Clin J Am Soc Nephrol, 2011, 6: 2599-2604. DOI: 10.2215/CJN.02400311
    [19]
    Ryan M, Ware K, Qamri Z, et al. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats[J]. Nephrol Dial Transplant, 2014, 29: 2228-2234. DOI: 10.1093/ndt/gft380
    [20]
    Ware K, Brodsky P, Satoskar AA, et al. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation[J]. J Am Soc Nephrol, 2011, 22: 1856-1862. DOI: 10.1681/ASN.2010101110
    [21]
    Brodsky SV, Nadasdy T, Rovin BH, et al. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate[J]. Kidney Int, 2011, 80: 181-189. DOI: 10.1038/ki.2011.44
    [22]
    Fordyce CB, Hellkamp AS, Lokhnygina Y, et al. On-Treatment Outcomes in Patients With Worsening Renal Function With Rivaroxaban Compared With Warfarin: Insights From ROCKET AF[J]. Circulation, 2016, 134: 37-47. DOI: 10.1161/CIRCULATIONAHA.116.021890
    [23]
    Bohula EA, Giugliano RP, Ruff CT, et al. Impact of Renal Function on Outcomes With Edoxaban in the ENGAGE AF-TIMI 48 Trial[J]. Circulation, 2016, 134: 24-36. DOI: 10.1161/CIRCULATIONAHA.116.022361
    [24]
    Jun M, James MT, Ma Z, et al. Warfarin Initiation, Atrial Fibrillation, and Kidney Function: Comparative Effective-ness and Safety of Warfarin in Older Adults With Newly Diagnosed Atrial Fibrillation[J]. Am J Kidney Dis, 2017, 69: 734-743. DOI: 10.1053/j.ajkd.2016.10.018
    [25]
    Stanifer JW, Pokorney SD, Chertow GM, et al. Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Advanced Chronic Kidney Disease[J]. Circulation, 2020, 141: 1384-1392. DOI: 10.1161/CIRCULATIONAHA.119.044059
    [26]
    Olesen JB, Lip GY, Kamper AL, et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease[J]. N Engl J Med, 2012, 367: 625-635. DOI: 10.1056/NEJMoa1105594
    [27]
    Kai B, Bogorad Y, Nguyen LN, et al. Warfarin use and the risk of mortality, stroke, and bleeding in hemodialysis patients with atrial fibrillation[J]. Heart Rhythm, 2017, 14: 645-651. DOI: 10.1016/j.hrthm.2017.01.047
    [28]
    Shah M, Avgil Tsadok M, Jackevicius CA, et al. Warfarin use and the risk for stroke and bleeding in patients with atrial fibrillation undergoing dialysis[J]. Circulation, 2014, 129: 1196-1203. DOI: 10.1161/CIRCULATIONAHA.113.004777
    [29]
    Chan KE, Lazarus JM, Thadhani R, et al. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation[J]. J Am Soc Nephrol, 2009, 20: 2223-2233. DOI: 10.1681/ASN.2009030319
    [30]
    Chang SH, Wu CV, Yeh YH, et al. Efficacy and Safety of Oral Anticoagulants in Patients With Atrial Fibrillation and Stages 4 or 5 Chronic Kidney Disease[J]. Am J Med, 2019, 132: 1335-1343. DOI: 10.1016/j.amjmed.2019.06.006
    [31]
    Dahal K, Kunwar S, Rijal J, et al. Stroke, Major Bleeding, and Mortality Outcomes in Warfarin Users With Atrial Fibrillation and Chronic Kidney Disease: A Meta-Analysis of Observational Studies[J]. Chest, 2016, 149: 951-959. DOI: 10.1378/chest.15-1719
    [32]
    Wong CX, Odutayo A, Emdin CA, et al. Meta-Analysis of Anticoagulation Use, Stroke, Thromboembolism, Bleeding, and Mortality in Patients With Atrial Fibrillation on Dialysis[J]. Am J Cardiol, 2016, 117: 1934-1941. DOI: 10.1016/j.amjcard.2016.03.042
    [33]
    Wang X, Tirucherai G, Marbury TC, et al. Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis[J]. J Clin Pharmacol, 2016, 56: 628-636. DOI: 10.1002/jcph.628
    [34]
    Chang M, Yu Z, Shenker A, et al. Effect of renal impair-ment on the pharmacokinetics, pharmacodynamics, and safety of apixaban[J]. J Clin Pharmacol, 2016, 56: 637-645. DOI: 10.1002/jcph.633
    • Related Articles

  • Cited by

    Periodical cited type(3)

    1. 袁茂叶，王春霞，张磊. 1例血液透析合并房扑患者抗凝治疗的病例分析. 临床医学研究与实践. 2025(09): 15-18 .
    2. 张丽莉，李静，丁林锋，孙静娴，蔡静波. 颈动脉粥样硬化斑块对非瓣膜性心房颤动病人缺血性脑卒中事件的预测价值. 实用老年医学. 2024(03): 236-239 .
    3. 魏莹叶，孙玉芹. 达比加群酯联合氯吡格雷治疗高龄非瓣膜性房颤伴不稳定型心绞痛的效果观察. 中国社区医师. 2022(33): 58-60 .

    Other cited types(1)

Catalog

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (603) PDF downloads (58) Cited by(4)
    Related
    Links: National Health Commission of the People's Republic of China Chinese Academy of Medical Sciences(CAMS) AMLC Check CNKI Database CNKI Term Online Chinese General Practice
    Address：Room 302,Third Floor,Building 7, No. 1 Shuaifuyuan, Wangfujing, Dongcheng District, Beijing 100730, China
    Tel：010-69154261/4262
    E - mail：medj@pumch.cn mjpumch@126.com
    Copyright of website：Editorial Office of Medical Journal of Peking Union Medical College Hospital

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return
    x Close Forever Close